Efficacy and acceptability of blue-wavelength light therapy for post-TBI behavioral symptoms: A systematic review and meta-analysis of randomized controlled trials

Links

Summary

This systematic review and meta-analysis evaluated blue-wavelength light therapy as a treatment for behavioral symptoms following traumatic brain injury, comparing it against placebo in randomized controlled trials. Findings have practical implications for implementing non-pharmacological light-based interventions in TBI rehabilitation settings to address fatigue, sleep disruption, and mood symptoms.

Key Findings

Blue-wavelength light therapy showed significant improvement in fatigue symptoms compared to placebo/control conditions in post-TBI patients
Light therapy demonstrated acceptable tolerability with low dropout rates, supporting its feasibility as a clinical intervention
Improvements were noted in daytime sleepiness and sleep quality outcomes, suggesting circadian-targeted light exposure as a viable adjunct therapy for TBI rehabilitation
Effect sizes and specific p-values varied across included RCTs; meta-analytic pooling indicated moderate benefit for fatigue and sleep-related behavioral symptoms

Categories

Sleep & Circadian Health: Blue-wavelength light therapy targets circadian entrainment to address post-TBI behavioral symptoms including sleep disturbances.

Mood & Mental Wellness: Post-TBI behavioral symptoms including mood dysregulation and fatigue are primary outcomes evaluated in this meta-analysis of RCTs.

Patient Recovery: Light therapy as a non-pharmacological intervention for TBI recovery outcomes has direct implications for rehabilitation and patient care settings.